Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-28
2011-06-28
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263220, C514S263230, C514S263300, C544S276000, C544S257000, C544S258000, C544S280000
Reexamination Certificate
active
07968556
ABSTRACT:
Provided herein are Heteroaryl Compounds having the following structure:wherein R1, R3, R4, L, X, Y, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
REFERENCES:
patent: 5424311 (1995-06-01), Billhardt-Troughton et al.
patent: 2004/0023921 (2004-02-01), Hong et al.
patent: 2004/0063658 (2004-04-01), Roberts et al.
patent: 2004/0097485 (2004-05-01), Burkitt et al.
patent: 2005/0009737 (2005-01-01), Clark
patent: 2008/0214580 (2008-09-01), Neagu et al.
patent: 2009/0069289 (2009-03-01), Neagu et al.
patent: 2009/0163545 (2009-06-01), Goldfarb
patent: 2009/0281075 (2009-11-01), Roughton et al.
patent: 2010/0144738 (2010-06-01), Bornmann et al.
patent: 2010/0249122 (2010-09-01), Kalman
patent: 2002100363 (2002-04-01), None
patent: WO 02/076954 (2002-10-01), None
patent: WO 03/093290 (2003-11-01), None
patent: WO 2005/003147 (2005-01-01), None
patent: WO 2006/050076 (2006-05-01), None
patent: WO 2006/087530 (2006-08-01), None
Registry File Document for RN 863501-03-5, 863502-39-0 and others (Sep. 20, 2005).
Hamad, Journal of Heterocyclic Chemistry vol. 38, Issue 4, pp. 939-944, Jul./Aug. 2001.
Coish, et al., 2006. “Small molecule inhibitors of IKK kinase activity,” Expert Opin. Ther. Patents, vol. 16(1):1-12.
Zaki et al., 2007, “The synthesis of imidazol[4.5-d]pyridines from a substituted imidazole and acyl or sulfonyl acetonitrile,” Tetrahedron, vol. 63(18):3745-3753.
Booth, et al., 1994, “Synthesis of 4- and 5-Disubstituted 1-Benzylimidazoles, Important Precursors of Purine Analogs,” J. of Heterocyclic of Chemistry, vol. 31(2):345-50.
Booth et al., 2001, “The Reactions of Diaminomaleonitrile with Isocyanates and Either Aldehydes or Ketones Revisited.” J. Org Chem, vol. 66:8436-8441.
Booth et al., 1995, “Synthesis of [1α, 2β, 3α-2,3-bis(benzyloxymethyl)cyclobutl]imidazol-5-amines: important precursors to cyclobut-A derivatives,” J. Chem Society, Perkin Tranactions 1: Organic and Bio-Organic Chemistry, vol. 6, pp. 669-675.
Booth et al., 1992, “Synthesis of 9-Hydroxyalkyl-substituted purines from the corresponding 4-(C-Cyanoformimidoyl)imidazole-5-amines,” J, Chem Society, Perkin Transactions 1: Organic and Bio-Organic Chemstry, vol. 2119-26.
Cohen, P. 2001, “The role of protein phosphorylation in human health and disease,” Eur. J. Biochem,vol. 268:5001-5010.
Cohen, P. 2002, “Protein kinases—the major drug targets of the twenty-first century?” Nature Reviews-Drug Discovery, vol. 1:309-315.
Dang et al., 1999, “Efficient synthesis of purines and purine nucelosides via an inverse electron demand diels—alder reaction,” J. Am Chem Soc., vol. 121(24):5833-5834.
Fabbro et al., 2002, “Protein kinasesas targets for anticancer agents: from inhibitors to useful drugs,” Pharm & Therapeutics, vol. 93:79-98.
Farhadi et al., 2006, “The role of protein kinase C isoforms in modulatinginjuty and repairof the intestinal barrier,” J. Pharm Exp. Ther., vol. 316(1):1-7.
Georgakis and Younes, 2006, “From rapi nui to rapamycin: targeting P13K/Akt/mTOR for cancer therapy,” Expert Rev. Anticancer Ther., vol. 6(1):131-140.
Irie et al., 2005, “Toward the development of new medicinal leads with selectivity for proteinkinase C isozymes,” The Chemical Record, vol. 5:185-195.
Park et al., 2000, “A novel mechanism of TRAF signaling revealed by structural and functionalanalyses of the TRADD-TRAF2 interaction,” Cell, vol. 101(7):777-787.
Seela et al., 2004, “Product Class 17: Purines,” Science of Synthesis, vol. 16, pp. 945-1108.
Sridhar et al., 2000, “Proteinkinases as therapeutic targets,” Pharm Research, vol. 17(11):1345-1353.
Westover et al., 1981, “Synthesis and antiviral activity of certain 9- β-D-Riofuranoaylpurine-6-carboxamides,” J.Med. Chem., vol. 24(8):941-46.
Ambinter Chemical Library as of Sep. 2006.
Interchem Chemical Library as of Sep. 2006.
Albers Ronald J.
Clareen Steven Spencer
Delgado Mederos Maria Mercedes
Hegde Sayee Gajanan
McKenna Jeffrey Mark
Berch Mark L
Jones Day
Signal Pharmaceuticals LLC
LandOfFree
Heteroaryl compounds, compositions thereof, and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl compounds, compositions thereof, and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl compounds, compositions thereof, and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2715300